A comparative study of preliminary dosimetry for human based on distribution data in rats with 111In, 90Y, 153Sm, and 177Lu labeled rituximab

Research output: Contribution to journalArticlepeer-review


  • Edalat Radfar
  • Amir R. Jalilian
  • Hassan Yousefnia
  • Ali Bahrami-Samani
  • Mohammad Ghannadi-Maragheh

Colleges, School and Institutes

External organisations

  • Radiopharmaceutical Research and Development Laboratory (RRDL)
  • Nuclear Science and Technology Research Institute (NSTRI)


Radio immunotherapy is one of the most important and effective therapies for B-cell non Hoddgkin's lymphoma treatment. Today, anti CD-20 antibodies labeled with beta emitter radionuclides are used in radio immunotherapy. Various radionuclides for labeling anti CD-20 antibodies have been studied and developed for the treatment and diagnosis of malignancies. This paper describes the preparation, bio-distribution and absorbed dose rate of 111In, 90Y, 177Lu, and 153Sm labeled anti CD-20 antibodies (rituximab) in human organs, after injection to rats. The macro cyclic bifunctional chelating agent, N-succinimidyl-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA-NHS) for conjugation to antibody, was used to prepare DOTA-rituximab. The conjugates were purified by molecular filtration, the average number of DOTA conjugated per mAb was calculated and total concentration was determined by spectrophotometric method. Radio-labeling was performed at 40 °C for 24 hours. After the quality control studies, the final radioactive solution was injected intravenously into rats through their tail vein. The tissue uptakes of each injection were measured. Then we calculated S values for 177Lu and 153Sm by using specific absorbed fractions and data used in the manner of radio-labeled analysis and dosimetry for humans. The absorbed dose rate of each organ was calculated in the specific time by medical internal radiation dose method with linear approximation in the activity measurements.

Bibliographic note

Copyright: Copyright 2018 Elsevier B.V., All rights reserved.


Original languageEnglish
Pages (from-to)144-151
Number of pages8
JournalNuclear Technology and Radiation Protection
Issue number2
Publication statusPublished - Jun 2012


  • Bio-distribution, Dosimetry, MIRD, Radio immunotherapy, Rituximab